Multiple Myeloma Clinical Trials
Multiple Myeloma clinical trials evaluate new drugs, immunotherapies, radiation approaches, and combination treatments for multiple Myeloma. Corterve aggregates actively recruiting Multiple Myeloma studies from the public ClinicalTrials.gov registry so you can browse them by location and eligibility. Many oncology trials enroll patients at different stages of disease, including newly diagnosed and previously treated. This is general information, not medical advice — review any study with your oncology care team before enrolling.
Recruiting Multiple Myeloma studies
- A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)NCT05519085PHASE3CelgeneLos Alamitos, California
- Tissue Collection for Studies of Lymph CancerNCT01676805National Cancer Institute (NCI)Bethesda, Maryland
- A Study to Evaluate Preventive Treatments for GPRC5D-related Oral EventsNCT06500884PHASE2Janssen Research & Development, LLCSan Francisco, California
- Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple MyelomaNCT06207799PHASE2M.D. Anderson Cancer CenterHouston, Texas
- A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple MyelomaNCT07589634PHASE2Janssen Research & Development, LLCBeverly Hills, California
- A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple MyelomaNCT07258511PHASE3Janssen Research & Development, LLCPhoenix, Arizona
- A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple MyelomaNCT07518186PHASE3Janssen Research & Development, LLCBirmingham, Alabama
- Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)NCT07609940PHASE4Regeneron PharmaceuticalsBaton Rouge, Louisiana
- Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple MyelomaNCT07096778PHASE2CellCentric Ltd.Phoenix, Arizona
- Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy ProtocolsNCT02682667National Cancer Institute (NCI)Bethesda, Maryland
- The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding AreasNCT07285044PHASE2Mayo ClinicJacksonville, Florida
- MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)NCT06152575PHASE3PfizerMobile, Alabama
Multiple Myeloma trials by state
Multiple Myeloma trials by metro
Frequently asked questions
- How do I find recruiting Multiple Myeloma clinical trials?
- Corterve aggregates actively recruiting Multiple Myeloma studies from the public ClinicalTrials.gov registry. Browse the studies listed on this page or take a free health assessment to see trials you may qualify for based on your profile.
- Are Multiple Myeloma clinical trials free to join?
- Study participation is typically free — research sponsors cover the cost of the investigational treatment and study-related visits. Many trials also compensate participants for time and travel. Details vary by study.
- Who can take part in a Multiple Myeloma clinical trial?
- Each study has its own eligibility criteria (for example age, disease stage, and prior treatments). This page is general information and not medical advice; discuss any specific trial with your healthcare provider to confirm whether it is appropriate for you.